Table 1. Clinicopathological Features of 440 Patients with Metastatic Prostate Cancer According to Site of Metastasis.
| Bone metastasis only | Visceral metastasis only | Bone and visceral metastases | |
|---|---|---|---|
| Number | 248 | 158 | 34 |
| Age (yrs) | 71.5 (66-77) | 72.1 (68-77) | 72 (67-78) |
| Body mass index (kg/m2) | 23.3 (21.1-25.1) | 23.5 (21.4-25.8) | 23.9 (21.8-26.3) |
| ECOG PS (≥1) | 65 (26.2%) | 32 (14.8%) | 9 (26.5%) |
| CCI (≥4) | 186 (75.0%) | 122 (77.2%) | 28 (82.3%) |
| VAS pain score (≥1) | 96 (38.7%) | 51 (23.7%) | 14 (41.2%) |
| Laboratory values | |||
| PSA (ng/mL) | 100.1 (33.4-389) | 60.6 (40.5-119) | 142.5 (81.9-448) |
| PSA nadir (ng/mL) | 1.21 (0.08-9.57) | 0.75 (0.03-5.8) | 1.41 (0.08-13.7) |
| Hemoglobin (gm/dL) | 12.1 (11.6-13.3) | 12.9 (11.7-14.2) | 12.5 (10.9-13.3) |
| ALP (IU/L) | 118.5 (75.2-294) | 79.0 (62.0-109) | 104.0 (89.5-147) |
| Gleason score (%) | |||
| ≤7 | 48 (19.4) | 49 (31.0) | 3 (8.9) |
| 8 | 90 (36.3) | 54 (34.2) | 18 (52.9) |
| ≥9 | 110 (44.3) | 55 (34.8) | 13 (38.2) |
| T stage (%) | |||
| ≤T2 | 18 (7.3) | 29 (18.4) | 2 (5.9) |
| T3 | 137 (55.2) | 76 (48.1) | 14 (41.2) |
| T4 | 93 (37.5) | 53 (33.5) | 18 (52.9) |
| Cytotoxic chemotherapy | 121 (48.8) | 31 (19.6) | 17 (50.0) |
ALP, alkaline phosphatase; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance score; PSA, prostate-specific antigen; VAS, Visual Analogue Scale.
Data are number (%) and median (IQR).